Founded in 2005, Korea Institute for Pharmaceutical Policy Affairs, KIPPA, is a non-profit, public foundation, approved by the Korean Ministry of Health and Welfare. The institute is contributed by three relevant parties, the Korean Pharmaceutical Association (KPA), the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA), and the Korea Pharmaceutical Distribution Association (KPDA).

KIPPA is a leading research center, which aims to promote public health through the development of policy regarding the rational use of medicines, pharmacy education, pharmacy practice, pharmaceutical industry, and pharmaceutical supply and distribution. In particular, we begin to develop ¡®a community pharmacy model as a health promotion center for community members¡¯. We are collecting and analysing big data accordingly to develop pharmacy-based policies, which pursue maximised pharmacy practice for all the Koreans.

In consequence, KIPPA will consistently implement research tailored to the promotion of health in the nation and worldwide. We kindly ask for supports from our fellow pharmacists, public and associations.

If you have any further enquiries about the institute or research in English, please contact us via e-mail (kippa.org@gmail.com).

Thank you.

Office Address
3FL, 194, Hyoryeong-ro, Seocho-gu, Seoul, Repbulic of Korea

ÇöÀçÀ§Ä¡ : Home : ¾Ë¸²¸¶´ç : ¿¬±¸¼Ò ´º½º
   
¾Ë¸²¸¶´ç
°øÁö»çÇ×
º¸µµÀÚ·á
ÀÎÀçä¿ë
 
 
Á¦   ¸ñ [´ëÇѾà»çÀú³Î]»ç·Ê °íÂûÀ» ÅëÇÑ ¹Ù¶÷Á÷ÇÑ ¾à»ç¿¬¼ö±³À°ÀÇ ¹æÇâ 4
³»   ¿ë

½º½º·Î ¡®¾÷±×·¹À̵塯 ÇÒ ¼ö ÀÖ´Â °úÁ¤ ÇÊ¿ä

»ç·Ê °íÂûÀ» ÅëÇÑ ¹Ù¶÷Á÷ÇÑ ¾à»ç¿¬¼ö±³À°ÀÇ ¹æÇâ 4

2020-04-06 06:00:31        ÁÖÇý¼º ±âÀÚ hsjoo@kpanews.co.kr

           
°æÁ¦¼ºÀå°ú ±×¿¡ µû¸¥ ³ëÀÎÀα¸ÀÇ Áõ°¡, ¸¸¼ºÁúȯÀÇ À¯º´À² Áõ°¡´Â º¸°ÇÀÇ·á¼­ºñ½ºÀÇ ¼ö¿ä¸¦ Áúº´ÀÇ Ä¡·á¿¡¼­ Áúº´ÀÇ °ü¸®·Î º¯È­½Ã۰í ÀÖ´Ù. ÀÌ·¯ÇÑ º¯È­´Â ÀǾàǰ º¹¿ë¿¡ À־µµ º¹¿ë¾à¹° Á¾·ùÀÇ Áõ°¡, º¹¿ë±â°£ÀÇ Àå±âÈ­ µîÀÇ º¯È­¸¦ ÃÊ·¡Çß´Ù. À̴ ÀǾàǰÀÇ Àü¹®°¡ÀΠ¾à»çµé¿¡°Ô ÀǾàǰÀÇ Á¦°ø¿¡¼­ ÀǾàǰ »ç¿ë°ü¸®(¾à·á)·Î ±× ¿ªÇÒÀ» È®´ë, °íµµÈ­ ½Ãų °ÍÀ» ¿ä±¸Çϰí ÀÖ´Ù. ¿ªÇÒÀÇ º¯È­´Â ±×¿¡ ¸Â´Â Àü¹®¼ºÀÌ ¼ö¹ÝµÅ¾ß Çϸç, µû¶ó¼­ º¸°ÇÀÇ·áÀü¹®°¡ ¿¬¼ö±³À° È¿À²È­¿Í À̸¦ ÅëÇÑ ¾àÁ¦¼­ºñ½ºÀÇ Áú °ü¸®´Â ÇʼöÀû »çÇ×ÀÌ µÆ´Ù. 
¿¬¼ö±³À°Àº ¾à»ç¹ý Á¦15Á¶, µ¿¹ý ½ÃÇà·É Á¦35Á¶ ¹× ½ÃÇà±ÔÄ¢ Á¦5Á¶¿¡ ÀǰÅÇØ ´ëÇѾà»çȸ°¡ º¸°Çº¹ÁöºÎ·ÎºÎÅÍ À§Å¹¹Þ¾Æ ½Ç½ÃÇϰí ÀÖÀ¸³ª, ¿¬¼ö±³À°ÀÇ ³»¿ë, ¹æ¹ý, Æò°¡ µî ¿©·¯ ºÐ¾ß¿¡¼­ ¿î¿µ ¹× °¨µ¶Ã¼°èÀÇ ºÎ½Ç¿¡ ´ëÇÑ ¹®Á¦Á¡ÀÌ Á¦±âµÇ°í ÀÖ´Ù. 
µû¶ó¼­ º»°í¿¡¼­´Â ¾à»ç¿¬¼ö±³À° ³»¿ëÀÇ Àü¹®¼ºÀ» È®º¸Çϰí, ±³À° °ü¸®¸¦ È¿À²È­ÇØ ¾àÁ¦¼­ºñ½ºÀÇ ÁúÀû Çâ»óÀ» ±âÇÒ ¼ö Àִ ¹Ù¶÷Á÷ÇÑ ¹æÇâÀ» Á¦½ÃÇØ º¸°íÀÚ ÇÑ´Ù. 
À̸¦ À§ÇØ, ¹Ì±¹, ÀϺ» µî ÁÖ¿ä±¹ÀÇ ¾à»ç¿¬¼ö±³À° ¹× ±¹³» Å¸ ÀÇ·áÀÎÀÇ º¸¼ö±³À° ¿î¿µÇöȲ ¹× °ü¸®Ã¼°è¸¦ °íÂûÇß´Ù.

III. ±¹³» ¿©Å¸ ÀÇ·áÀÎÀÇ º¸¼ö±³À°
¡âÄ¡°úÀÇ»çÀÇ º¸¼ö±³À°
Ä¡°úÀǻ砺¸¼ö±³À° ´ë»óÀڴ ¿¬ 8Á¡ ÀÌ»óÀÇ º¸¼ö±³À°À» À̼öÇØ¾ß ÇÑ´Ù. ÀÇ·á¹ý½ÃÇà±ÔÄ¢¿¡ µû¶ó º¸¼ö±³À°À» ½Ç½ÃÇÒ ¼ö Àִ ±â°üÀº <Ç¥4>ÀÇ ±â°ü Áß¿¡¼­ ´ëÇÑÄ¡°úÀÇ»çÇùȸÀÇ Á¤°ü¿¡ µû¶ó ÀÎÁõÀ» ¹ÞÀº ±â°üÀ¸·Î Çϰí ÀÖ´Ù.


±³À°±â°üÀº ´ëÇÑÄ¡°úÀÇ»çÇùȸ ¹× ÁöºÎ°¡ 19°³(15.8%), ºÐ°úÇÐȸ°¡ 35°³(29.2%), Ä¡°ú´ëÇÐ?Ä¡ÀÇÇÐÀü¹®´ëÇпø¡¤ÀÓ»óÄ¡ÀÇÇдëÇпø 16°³(13.3%), ¼ö·ÃÄ¡°úº´¿ø 46°³(38.3%), ±âŸ 4°³(0.3%)·Î ÃÑ 120°³ÀÇ ±â°ü(2018³â ±âÁØ)ÀÌ ÀÖ´Ù. 

ÀϹÝÀûÀ¸·Î ±³À° ¹æ¹ýÀº °­ÀÇ Áß½ÉÀÇ ±³À°Àº Áö¾çÇϵǠ½Ãû°¢ ±³À縦 È°¿ëÇϰųª ½Ç½À±³À° À§ÁַΠ½Ç½ÃµÈ´Ù. ´ëÇÑÄ¡°úÀÇ»çÇùȸÀÇ º¸¼ö±³À°¼¾ÅÍ¿¡¼­´Â ¿Â¶óÀΠº¸¼ö±³À°À» Á¦°øÇϰí ÀÖÀ¸¸ç, °­ÀǺ°·Î ¼ö°­·á¸¦ °áÁ¦ÇÑ ÈÄ ±³À° À̼ö°¡ °¡´ÉÇÏ´Ù. °¢ º¸¼ö±³À° Á¾·ùº°·Î ÀÎÁ¤Çϴ »óÇÑ ÆòÁ¡Àº <Ç¥5>°ú °°´Ù.


¡âÇÑÀÇ»çÀÇ º¸¼ö±³À°
ÇÑÀǻ砺¸¼ö±³À°À» ÁÖ°üÇϴ ´ëÇÑÇÑÀÇ»çÇùȸ´Â 2010³âºÎÅÍ °ø½ÄÀûÀ¸·Î º¸¼ö±³À°¼¾Å͸¦ ¿î¿µ ÁßÀÌ´Ù. º¸¼ö±³À°¼¾Åʹ ´Ù¾çÇÑ ±³À° ¼ö¿ä¿Í Àü¹®È­µÈ ÇнÀ ¿ä±¸¸¦ ½Å¼ÓÈ÷ ¼ö¿ëÇØ ÇÑÀÇ»çµéÀÌ ±³À° ¼±ÅÃÀÇ ÆøÀ» ³ÐÈú ¼ö ÀÖµµ·Ï ¿µ¿ªº° ±³À° °úÁ¤À» °³¹ß¡¤¿î¿µÇÏ°í ½Ã°£°ú °ø°£ÀÇ Á¦¾àÀ» ¹ÞÁö ¾Ê´Â »çÀ̹ö ±³À°À» ÅëÇØ ±³À° ±âȸ¸¦ È®´ëÇϰíÀÚ Çϴ µîÀÇ ÃëÁö·Î ¼³¸³µÆ´Ù.

±³À° ³»¿ëÀº °¡±ÞÀû ½ÇÁ¦ ÀÓ»ó¿¡ ÇÊ¿äÇÑ ÀÇ·á ±â¼úÀ̳ª ÃֽŠÇÑÀÇÇРÁ¤º¸¸¦ ¾Ë¸®´Â µ¥ ÁßÁ¡À» µÖ ±¸¼ºÇϰí, ±× ¿Ü¿¡ ÇÑÀǻ翡°Ô ÇÊ¿äÇÑ ÀϹݠ°­Á³ª ÀÇ·áÀ±¸® ±³À°À» ½Ç½ÃÇÒ ¼ö ÀÖ´Ù. 

´ëÇÑÇÑÀÇ»çÇùȸÀÇ º¸¼ö±³À°±ÔÁ¤¿¡ µû¸£¸é º¸¼ö±³À° ³»¿ëÀº °úÇÐÀû ±Ù°Å¿¡ ±â¹ÝÀ» µÐ ³»¿ëÀ» Áß½ÉÀ¸·Î ÇϵǠÀÓ»óÇÑÀÇÇÐ, ±âÃÊÇÑÀÇÇÐ, ÇÑÀǾà ÃֽŠÁö°ß, ÇÑÀǾà Á¤Ã¥ Çö¾È, ÀÇ·áÀ±¸® ¹× ÀÇ·á¹ý µîÀÇ Æø³ÐÀº ÁÖÁ¦¿¡ ´ëÇÑ Á¤º¸¸¦ Æ÷ÇÔÇϰí ÀÖ¾î¾ß ÇÑ´Ù. 

¶ÇÇÑ, ÀÇ·áÀ±¸® ¹× ÀÇ·á¹ý °ü·Ã º¸¼ö±³À°À» ¿¬ 1ÆòÁ¡ ÀÌ»ó Àǹ«ÀûÀ¸·Î À̼öÇØ¾ß Çϸç ÇØ´ç ±³À°Àº ¿øÄ¢ÀûÀ¸·Î ½ÃµµÁöºÎ¿¡¼­ ´ã´çÇÑ´Ù.

´ëÇÑÇÑÀÇ»çÇùȸ´Â 2008³â º¸¼ö±³À°±ÔÁ¤À» °³¼±ÇØ »çÀ̹ö º¸¼ö±³À°ÀÇ ÆòÁ¡À» ÀÎÁ¤Çϱ⠽ÃÀÛÇß°í 2009³âºÎÅÍ »çÀ̹ö º¸¼ö±³À°¼¾Å͸¦ ½ÃÇè °¡µ¿, 2010³âºÎÅÍ Á¤½Ä ¿î¿µ¿¡ µé¾î°¬´Ù. »çÀ̹ö º¸¼ö±³À°¼¾Å͸¦ ÅëÇØ Á¦°øµÇ´Â º¸¼ö±³À° ¿Â¶óÀΠ°­ÁµéÀº <Ç¥6>°ú °°ÀÌ ÁÖÁ¦°¡ ´Ù¾çÇÏ´Ù.


³ª°¡¸ç
ÃÖ±Ù ÀǾà È¯°æÀÌ ºü¸¥ ¼Óµµ·Î º¯È­Çϰí Àִ °¡¿îµ¥, ÀǾàǰ °ü¸® ¹× º¹¾àÁöµµÀÇ Àü¹®¼ºÀÌ ¿ä±¸µÇ°í À־à»ç ÀηÂÀÇ Æò»ý±³À° ¶Ç´Â Àç±³À° Â÷¿ø¿¡¼­ÀÇ ³»½Ç Àִ ¿¬¼ö±³À°ÀÌ ÇÊ¿äÇÑ ½ÃÁ¡À̶ó°í ÇϰڴÙ. 

º»°í¿¡¼­´Â ¹Ì±¹?ÀϺ»ÀÇ ¾à»ç¿¬¼ö±³À°°ú ¿ì¸®³ª¶ó Å¸ ÀÇ·áÀÎÀÇ º¸¼ö±³À° ½Ç½Ã ÇöȲÀ» »ìÆìº½À¸·Î½á ¿ì¸®³ª¶ó ¾à»çÀÇ Àü¹®¼º °­È­¸¦ ÅëÇÑ ¾àÁ¦ ¼­ºñ½ºÀÇ ÁúÀû Çâ»óÀ» µµ¸ðÇÒ ¼ö Àִ ¹Ù¶÷Á÷ÇÑ ¾à»ç¿¬¼ö±³À° ¹æÇâÀ» Á¦½ÃÇϰíÀÚ Çß´Ù.    

¿ì¼± ¹Ì±¹°ú ÀϺ»ÀÇ ¾à»ç¿¬¼ö±³À°¿¡¼­ ¿ì¸®³ª¶ó ¾à»ç¿¬¼ö±³À°ÀÌ ÃëÇÒ ¼ö Àִ ½Ã»çÁ¡À¸·Î´Â ¾à»ç ÀÚ½ÅÀÇ Àü¹®´É·Â°³¹ß(Continuing Professional Development, CPD) ÇнÀ ¹æ½ÄÀ» ²ÅÀ» ¼ö ÀÖ°Ú´Ù. 

Àü¹®´É·Â°³¹ß ¹æ½ÄÀº ¾à»ç¿¬¼ö±³À°¿¡¼­ Á¡Â÷ ±× ºñÁßÀÌ È®´ëµÇ°í Àִ ¹æ½ÄÀε¥, ¾à»ç ÀÚ½ÅÀÌ ÇÊ¿ä·Î Çϴ ³»¿ëÀÇ ¿¬¼ö±³À°À» ¼±ÅÃÇØ ¼ö°­Çϰųª, ¶Ç´Â °³ÀÎÀûÀ¸·Î Ã¥(Àú³Î), TV?ÀÎÅͳݠµîÀ» ÀÌ¿ëÇØ ¾à·á °ü·Ã ºÐ¾ß¸¦ ÇнÀÇÔÀ¸·Î½á ¾à»ç ÀÚ½ÅÀÇ ºÎÁ·ÇÑ Àü¹®¼ºÀ» ÃæÁ·½ÃÄÑ ³ª°¡´Â ¿¬¼ö±³À° ¹æ½ÄÀΠ°ÍÀÌ´Ù.           

À̿͠°°Àº ¿Ü±¹ÀÇ ¾à»ç¿¬¼ö±³À° µ¿ÇâÀ» °í·ÁÇØ, ¾à»ç ½º½º·Î ºÎÁ·ÇÏ´Ù°í ´À³¢°Å³ª, º¸´Ù Àü¹®ÀûÀΠ³»¿ëÀ» ½ÀµæÇÏ°í ½ÍÀº °æ¿ì¿¡ ±³À° ¼±ÅÃÀÇ ÆøÀ» ³ÐÈú ¼ö ÀÖµµ·Ï ¿ì¸®³ª¶ó ¾à»ç¿¬¼ö±³À°¿¡¼­µµ ¼±Åðú¸ñÀ» ´Ù¾çÈ­Ç졒ʱ³À° À¯Çüµµ ´ë¸é±³À° À̿ܿ¡ ´Ù¾çÇÑ ¹æ½ÄÀ» Àû±ØÀûÀ¸·Î È°¿ëÇÒ Çʿ䰡 ÀÖÀ» °ÍÀÌ´Ù. 

ƯÈ÷ ¿Â¶óÀΠ±³À°ÀÇ °æ¿ì ¿Ü±¹ÀÇ ¾à»ç¿¬¼ö±³À°»Ó¸¸ ¾Æ´Ï¶ó ±¹³» Å¸ ÀÇ·áÀÎÀÇ º¸¼ö±³À°¿¡¼­µµ À̹̠Çʼö°ú¸ñÀ» Æ÷ÇÔÇÑ ¸¹Àº °­Á¸¦ ¿Â¶óÀΠ¹æ½ÄÀ¸·Î Á¦°ø Çϰí Àִ °ÍÀ¸·Î ÆÄ¾ÇµÇ´Â ¹Ù, ¾ÆÁ÷±îÁö ¸Å¿ì Á¦ÇÑÀûÀ¸·Î Á¦°øµÇ°í Àִ ¿ì¸®ÀÇ ¿Â¶óÀΠ±³À°¹æ½ÄÀ» Á¤±Ô ±³À°¹æ½ÄÀ¸·Î Ã¤ÅÃÇØ È®´ë, °­È­ÇÔÀ¸·Î½á ¾à»çµéÀÌ ½Ã¡¤°ø°£Àû Á¦¾à¿¡¼­ ¹þ¾î³ª°Ô²û Çϴ °ÍÀÌ ¾à»çÀÇ Àü¹®¼º Çâ»óÀ» À§ÇÑ ¿¬¼ö±³À°ÀÇ Âü¿©À² Á¦°í·Î À̾îÁú °ÍÀÌ´Ù. 

¶Ç ÇöÀçÀÇ ÇöÀå ¼³¹® À§ÁַΠÁøÇàµÇ´Â ¿¬¼ö±³À° Æò°¡¹æ½ÄÀÇ ÇѰèÁ¡À» °³¼±ÇØ ¾à»çµéÀÇ ¼ö¿ä¸¦ ÆÄ¾ÇÇÒ ¼ö Àִ ±¸Ã¼È­µÈ Æò°¡¸¦ ½Ç½ÃÇϰí, ±× Æò°¡ °á°ú°¡ ´ÙÀ½ ³âµµ ¿¬¼ö±³À°ÀÇ ³»¿ëÀ̳ª ±³À° ¹æ½Ä µî¿¡ ¹Ý¿µµÈ´Ù¸é ¾àÁ¦ ¼­ºñ½ºÀÇ ÁúÀû Çâ»ó¿¡ Á÷Á¢ÀûÀ¸·Î À̹ÙÁöÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î »ç·áµÈ´Ù.



 

¹øÈ£ ÷ºÎ Á¦¸ñ ÀÛ¼ºÀÚ ÀÛ¼ºÀÏ Á¶È¸
9 [µ¥Àϸ®ÆÊ]¾à±¹ Á÷¿ø ¾÷¹«¹üÀ§ ÇØ¿Üµµ '±Ø°ú ±Ø'¡¦±¹³»´Â ¾î¶»°Ô? ±è¼±Èñ 2020-04-09 1140
8 [¾à»ç°ø·Ð]ÀǾàǰÁ¤Ã¥¿¬, Áö¿ª¾à±¹ ¸ðµ¨ ¿Ï¼º ³ë·Â¡¦Á¤±âÀÌ»çȸ °³ÃÖ ±è¼±Èñ 2020-04-09 735
7 [µ¥Àϸ®ÆÊ]ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò, ¿Â¶óÀÎ ÀÌ»çȸ ¿­°í »ç¾÷ È®Á¤ ±è¼±Èñ 2020-04-09 752
6 [´ëÇѾà»çÀú³Î]»ç·Ê °íÂûÀ» ÅëÇÑ ¹Ù¶÷Á÷ÇÑ ¾à»ç¿¬¼ö±³À°ÀÇ ¹æÇâ 4 ±è¼±Èñ 2020-04-09 721
5 [´ëÇѾà»çÀú³Î]»ç·Ê °íÂûÀ» ÅëÇÑ ¹Ù¶÷Á÷ÇÑ ¾à»ç¿¬¼ö±³À°ÀÇ ¹æÇâ 3 ±è¼±Èñ 2020-04-09 627
4 [´ëÇѾà»çÀú³Î]»ç·Ê °íÂûÀ» ÅëÇÑ ¹Ù¶÷Á÷ÇÑ ¾à»ç¿¬¼ö±³À°ÀÇ ¹æÇâ 2 ±è¼±Èñ 2020-03-24 737
3 [ÄíŰ´º½º]WHO, Àü¼¼°è ¸¶½ºÅ© »ý»ê·® 40% Áõ°¡ ÇÊ¿ä ±è¼±Èñ 2020-03-16 1226
2 [´ëÇѾà»çÀú³Î]¹Ì±¹, ½Ã´ë ¸ÂÃç ±³À°°ú¸ñ º¯È­¡¦»çÈÄÆò°¡µµ Àǹ«È­ ±è¼±Èñ 2020-03-16 922
1 [´ëÇѾà»çÀú³Î]ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò ¸®Æ÷Æ®: Ä¿¹Â´ÏƼÄɾî, ¼¼°èÀÇ ´äÀº ¡®¾à»ç¡¯¿´´Ù ±è¼±Èñ 2020-03-10 981

ÀÌÀü 10ÆäÀÌÁö [1]  [2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  ´ÙÀ½ 10ÆäÀÌÁö

 
 

¼­¿ï ¼­Ãʱ¸ È¿·É·Î194, 3Ãþ (Àç)ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò TEL : 02) 3474-5301 / FAX : 02)3474-5306

COPYRIGHT (C) 2006 KOREA INSTITUTE FOR PHARMACEUTICAL POLICY AFFAIRS ALL RIGHTS RESERVED. FOR MORE INFORMATION MAL kippa.org@gmail.com

±âºÎ±Ý ¾È³»